Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4

Add time:07/14/2019    Source:sciencedirect.com

Herein, we embarked on a structural optimization campaign aiming at the discovery of second generation anti-angiogenesis agents with our previously reported BPS-7 as lead compound. A library of 27 compounds has been afforded based on the highly conserved ATP-binding pocket of VEGFR-2, Tie-2, and EphB4. Several title compounds exhibited simultaneous inhibitory effects against three angiogenic RTKs. These compounds with a ‘triplet’ inhibition profile have been identified as novel anti-angiogenic and anticancer agents. The representative VDAU11 displayed prominent anti-angiogenic and anticancer potency and could be considered as a candidate for further optimization. These results indicate that N-(pyridin-2-yl)acrylamide could serve as a novel hinge-binding group of triple inhibitors.

We also recommend Trading Suppliers and Manufacturers of 2-(4-methylphenyl)-2-oxoethyl 2-(4-isopropylphenyl)-4-quinolinecarboxylate (cas 355433-37-3). Pls Click Website Link as below: cas 355433-37-3 suppliers

Prev:Axially chiral bis(α-amino acid)s and dioxopiperazines. Synthesis and configurational assignment
Next:Reversal of cardiac vagal effects of physostigmine by adjunctive muscarinic blockade)